目的筛选和鉴定人乳头状瘤病毒11型E7抗原（HPV11E7）HLA-A＊0201限制性细胞毒性T淋巴细胞（cytotoxic T lymphocyte，CTL）表位。方法预测HPV11E7抗原HLA-A＊0201限制性CTL表位并合成相对应的表位多肽和四聚体（tetramer），即HPV11E7 ...目的筛选和鉴定人乳头状瘤病毒11型E7抗原（HPV11E7）HLA-A＊0201限制性细胞毒性T淋巴细胞（cytotoxic T lymphocyte，CTL）表位。方法预测HPV11E7抗原HLA-A＊0201限制性CTL表位并合成相对应的表位多肽和四聚体（tetramer），即HPV11E7 7-15（TLKDIVLDL）、15-23（LQPPDPVGL）、47-55（PLTQHYQIL）、81-89（DLLLGTLNI）和82-90（LLLGTLNIV）。从健康HLA-A＊0201成人外周血单一核细胞诱导树突状细胞（DC）并负载上述表位多肽，流式细胞技术检测DC成熟分化标记及ELISA法检测DC分泌的IL-12；成熟DC负载各组多肽后观察DC激活T淋巴细胞的效应，ELISA法检测T细胞分泌的IFN-γ；四聚体检测抗原特异性CD8^＋T细胞及乳酸脱氢酶（LDH）释放法评价DC诱导的CTL对靶细胞的特异性体外杀伤效应。结果预测的5条HPV11ET表位多肽均能诱导DC的成熟分化；E77-15、82-90和15-23多肽负载的DC能激活T淋巴细胞分泌高水平IFN-γ；E77-15多肽负载的DC能刺激特异性tetramer^＋CD8^＋细胞增殖且其诱导的CTL对HPV11E7／293细胞产生高效率的特异性杀伤作用（P〈0．05）。结论筛选并鉴定出1条HPV11E7HL-A＊0201限制性CTL表位E77-15（TLKDIVLDL），负载该表位肽的DC体外可诱导高效、特异性的CTL效应，抗原性较强，有可能作为HPV感染治疗用肽疫苗的候选表位。展开更多
Objective: To established methods for cryopreserving peripheral blood mononuclear cells (PBMCs) andproducing DCs from cryopreserved PBMCs. Methods:Mature DCs were generated from cryopreserved PBMCs by using IL-4, GM...Objective: To established methods for cryopreserving peripheral blood mononuclear cells (PBMCs) andproducing DCs from cryopreserved PBMCs. Methods:Mature DCs were generated from cryopreserved PBMCs by using IL-4, GM-CSF, TNF-a, IL-1b, IL-6, pgE2 and LPS. The phenotype of the resultant DCs was investigated by flow cytometry. The functions of the resultant DCs were verified by Elispot assay. Results: The resultant DCs expressed high levels of HLA ABC, HLA DR, costimulatory molecules and the DC maturation marker CD83. The mature DCs wegenerated from frozen PBMCs were able to prime CD8 T cells into long term IFN-g producing peptide specific CTL. Conclusion: The DCs we developed from cryopreservedPBMC were fully mature and had the capability tostimulate immune reaction. Thus, we developed a method to generate functional mature DC from cryopreservedPBMC.展开更多
鼻咽癌(Nasopharyngeal carcinoma,NPC)与EB病毒(Epstein-Barr virus,EBV)感染密切相关。鼻咽癌细胞中表达的EB病毒潜伏膜蛋白2(Latent membrane protein 2,LMP2)是免疫疗法的理想靶抗原。靶向EBV-LMP2疫苗已被证明是安全有效的,可在NP...鼻咽癌(Nasopharyngeal carcinoma,NPC)与EB病毒(Epstein-Barr virus,EBV)感染密切相关。鼻咽癌细胞中表达的EB病毒潜伏膜蛋白2(Latent membrane protein 2,LMP2)是免疫疗法的理想靶抗原。靶向EBV-LMP2疫苗已被证明是安全有效的,可在NPC患者体内增强特异性细胞毒性T淋巴细胞(Cytotoxic T lymphocyte,CTL)应答。目前面临的挑战是如何提高NPC患者的临床反应率,其关键在于阐明LMP2特异性CTL的细胞毒性。为研究rAd-LMP2疫苗诱导的LMP2A特异性CTL对肿瘤细胞的杀伤效果,本研究利用rMVA-LMP2-GFP感染P815细胞(H-2d)构建表达EBV-LMP2A和GFP蛋白的P815-LMP2-GFP靶细胞,用rAd-LMP2疫苗免疫BALB/c小鼠(H-2d)来诱生LMP2A特异性的CTL细胞作为效应细胞。然后,应用活细胞成像技术观察LMP2A特异性CTL对P815-LMP2-GFP靶细胞的杀伤过程。结果显示成功构建了P815-LMP2-GFP靶细胞和LMP2A特异性CTL效应细胞,并以成像的方式实时动态记录了LMP2A特异性CTL识别并杀死靶细胞的过程。P815-LMP2-GFP靶细胞可在2h内被LMP2A特异性CTL识别并杀伤。本研究建立了一种直接监测LMP2A特异性CTL识别并杀伤靶细胞过程的动态可视化方法。因此,本研究为肿瘤疫苗的体外抗肿瘤免疫效果的研究提供了新手段和新思路。展开更多
文摘目的筛选和鉴定人乳头状瘤病毒11型E7抗原（HPV11E7）HLA-A＊0201限制性细胞毒性T淋巴细胞（cytotoxic T lymphocyte，CTL）表位。方法预测HPV11E7抗原HLA-A＊0201限制性CTL表位并合成相对应的表位多肽和四聚体（tetramer），即HPV11E7 7-15（TLKDIVLDL）、15-23（LQPPDPVGL）、47-55（PLTQHYQIL）、81-89（DLLLGTLNI）和82-90（LLLGTLNIV）。从健康HLA-A＊0201成人外周血单一核细胞诱导树突状细胞（DC）并负载上述表位多肽，流式细胞技术检测DC成熟分化标记及ELISA法检测DC分泌的IL-12；成熟DC负载各组多肽后观察DC激活T淋巴细胞的效应，ELISA法检测T细胞分泌的IFN-γ；四聚体检测抗原特异性CD8^＋T细胞及乳酸脱氢酶（LDH）释放法评价DC诱导的CTL对靶细胞的特异性体外杀伤效应。结果预测的5条HPV11ET表位多肽均能诱导DC的成熟分化；E77-15、82-90和15-23多肽负载的DC能激活T淋巴细胞分泌高水平IFN-γ；E77-15多肽负载的DC能刺激特异性tetramer^＋CD8^＋细胞增殖且其诱导的CTL对HPV11E7／293细胞产生高效率的特异性杀伤作用（P〈0．05）。结论筛选并鉴定出1条HPV11E7HL-A＊0201限制性CTL表位E77-15（TLKDIVLDL），负载该表位肽的DC体外可诱导高效、特异性的CTL效应，抗原性较强，有可能作为HPV感染治疗用肽疫苗的候选表位。
文摘Objective: To established methods for cryopreserving peripheral blood mononuclear cells (PBMCs) andproducing DCs from cryopreserved PBMCs. Methods:Mature DCs were generated from cryopreserved PBMCs by using IL-4, GM-CSF, TNF-a, IL-1b, IL-6, pgE2 and LPS. The phenotype of the resultant DCs was investigated by flow cytometry. The functions of the resultant DCs were verified by Elispot assay. Results: The resultant DCs expressed high levels of HLA ABC, HLA DR, costimulatory molecules and the DC maturation marker CD83. The mature DCs wegenerated from frozen PBMCs were able to prime CD8 T cells into long term IFN-g producing peptide specific CTL. Conclusion: The DCs we developed from cryopreservedPBMC were fully mature and had the capability tostimulate immune reaction. Thus, we developed a method to generate functional mature DC from cryopreservedPBMC.
文摘鼻咽癌(Nasopharyngeal carcinoma,NPC)与EB病毒(Epstein-Barr virus,EBV)感染密切相关。鼻咽癌细胞中表达的EB病毒潜伏膜蛋白2(Latent membrane protein 2,LMP2)是免疫疗法的理想靶抗原。靶向EBV-LMP2疫苗已被证明是安全有效的,可在NPC患者体内增强特异性细胞毒性T淋巴细胞(Cytotoxic T lymphocyte,CTL)应答。目前面临的挑战是如何提高NPC患者的临床反应率,其关键在于阐明LMP2特异性CTL的细胞毒性。为研究rAd-LMP2疫苗诱导的LMP2A特异性CTL对肿瘤细胞的杀伤效果,本研究利用rMVA-LMP2-GFP感染P815细胞(H-2d)构建表达EBV-LMP2A和GFP蛋白的P815-LMP2-GFP靶细胞,用rAd-LMP2疫苗免疫BALB/c小鼠(H-2d)来诱生LMP2A特异性的CTL细胞作为效应细胞。然后,应用活细胞成像技术观察LMP2A特异性CTL对P815-LMP2-GFP靶细胞的杀伤过程。结果显示成功构建了P815-LMP2-GFP靶细胞和LMP2A特异性CTL效应细胞,并以成像的方式实时动态记录了LMP2A特异性CTL识别并杀死靶细胞的过程。P815-LMP2-GFP靶细胞可在2h内被LMP2A特异性CTL识别并杀伤。本研究建立了一种直接监测LMP2A特异性CTL识别并杀伤靶细胞过程的动态可视化方法。因此,本研究为肿瘤疫苗的体外抗肿瘤免疫效果的研究提供了新手段和新思路。
